ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 03 May 2017
Last Updated on 03 May 2017

A- A+

Guidance Recommendations

Following an evaluation of gemcitabine for advanced bladder cancer and non-small-cell lung cancer, the MOH Drug Advisory Committee has recommended to list gemcitabine 1g, 2g and 200mg on the MOH Standard Drug List 2 (SDL2) in view of its comparable clinical efficacy and safety to other standard chemotherapy regimens and low annual cost of subsidy.

This recommendation means that subsidies will apply to gemcitabine for the indications registered in Singapore:

First-line treatment of locally advanced or metastatic non-small cell lung cancer in combination with cisplatin and palliative treatment of adult patients with locally advanced or metastatic non-small cell lung cancer;
Treatment of adult patients with locally advanced or metastatic adenocarcinoma of the pancreas;
Treatment of advanced bladder cancer in combination with cisplatin;
Treatment of unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant or neoadjuvant chemotherapy in combination with paclitaxel.

Gemcitabine for Cancer (May 2017)